Ask AI
Redefining HCC Treatment in the Immunotherapy Era

CE / CME

Redefining HCC Treatment in the Immunotherapy Era – Expert Insights, Multimodal Innovations, and Coordinated Care for Optimal Outcomes Across the Disease Continuum

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Released: June 26, 2025

Expiration: December 25, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How would you rate your confidence in collaborating with interventional radiologist and other members of the care team when appropriate to enhance patient-centered management of advanced HCC?

2.

Patient Case: 72-Yr-Old Woman With MASH Cirrhosis



  • 72-yr-old woman presents with MASH cirrhosis presents to the clinic

  • Patient’s MRI imaging revealed a liver lesion

    • LI-RADS 5 lesion measuring 6 x 5 cm

    • Possible secondary lesion (LIRADS 4/ Next slide)



  • ECOG PS: 1

  • Child-Pugh score: 5



Patient Case: Secondary Lesion on MRI Identified—LIRADS 4



  • Primary management is being considered

  • No portal vein involvement was identified


In a consultation with a patient to discuss treatment options, which of the following would you mention regarding the efficacy data for adding systemic immunotherapy to TACE based on the LEAP-012 and EMERALD-1 trials?

3.

In a patient receiving lenvatinib plus pembrolizumab and TACE, as in the LEAP-012 clinical trial, which of the following approaches would you recommend for management of grade 3 pancreatitis?